MAIA Biotechnology, Inc. (MAIA) is a Healthcare stock trading at $1.39 (as of 2026-08-21), with a market capitalization of $84.55M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
MAIA Biotechnology, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of cancer therapies, primarily for non-small cell lung cancer. Its lead investigational candidate, THIO, is designed around telomere targeting and immunogenicity. The company is based in Chicago and was founded in 2018.
Understand MAIA Biotechnology, Inc.: how it makes money
MAIA Biotechnology develops investigational cancer therapies, led by THIO, which uses telomere targeting and immunogenicity, and it makes money in the future through successful clinical development and commercialization rather than current product sales.
As a clinical-stage biotech with no reported revenue, MAIA's profit model depends on THIO moving from investigational clinical results to regulatory approval and eventual commercialization.
Business quality (Weak): High uncertainty but with clear, trackable clinical outcome metrics for THIO, current financials show no revenue generation and very large negative operating margin.
Bull case
Defined lead asset and mechanism: The companys lead asset THIO is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity for cancer, primarily non-small cell lung cancer.
Global clinical execution footprint: THIO-101 has active clinical trial sites in 6 countries across Europe and Asia, with 44 active trial sites.
Survival-focused clinical signals are tracked: Reported operating KPIs for THIO include Estimated Median Overall Survival of 17.8 and Estimated Median Progression Free Survival in third-line treatment (180 mg dose) of 5.6.
Bear case
No current revenue: As of 2025-06-30, revenue is 0.0B, indicating the company is not yet selling an approved product.
Very large operating losses: The operating margin is -6482.1 as of 2025-06-30, reflecting heavy ongoing costs typical of clinical-stage development.
Clinical outcome risk: Key survival metrics are presented as estimates with confidence interval bounds (for example, 95% confidence interval lower bound for overall survival of 12.5), which underscores uncertainty and the possibility of outcomes not meeting thresholds.
Trial scale and completion are limited in the provided data: Provided THIO-101 data includes 79 patients treated in parts A and B and up to 48 participants enrolling in part C, with maximum phase 3 patient enrollment of 300, leaving meaningful execution and outcome uncertainty.